Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.

Fiche publication

Date publication

décembre 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr NARDIN Charlée

Tous les auteurs :
Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36578943

Résumé

Adverse events (AEs) of immune checkpoint inhibitors (ICIs) are frequent and mainly due to an overactivity of the immune system leading to excessive inflammatory responses (immune-related AE) that can affect any organ of the body. Beside the most frequent AEs, there are rare AEs whose diagnosis and treatment can be challenging. We report here a singular case of capillary leak syndrome (CLS) associated with chylothorax occurring in a patient who has been treated with adjuvant nivolumab (anti-PD1) for resected AJCC stage IIB primary melanoma.